Eli Lillys obesity pill remains a viable rival to Novos oral Wegovy despite data that underwhelmed investors

Source: cnbc.com

Image Credit: cnbc.com

Please find more details at cnbc.com

Summary

Eli Lillys orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and easier manufacturing.

Source: cnbc.com

Read More

(0)

Exclusive AI-Powered News Insights (For Members only)

Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!